Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

The number of biopharma professionals let go has increased year over year for three straight months. In July, nearly 8,000 ...

The FDA is allowing Sarepta to resume shipments of Elevidys (delandistrogene moxeparvovec) to ambulatory patients with Duchenne muscular dystrophy.

While the deaths occurred in patients who had been treated with Agios’ anemia treatment Pyrukynd, the biotech insisted in an ...